|
|
|
 |
| Location: Home -
Products - Reference Compounds&Impurities - Anti-Cancer(Oncology) Agents
|
LCL-161
| Catalogue No. : |
C16407 |
| Product Name: |
LCL-161 |
| Synonym: |
LCL-161;LCL 161;LCL161 |
| Chemical Name: |
(2S)-N-[(1S)-1-Cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-propanamide |
| CAS No. : |
1005342-46-0 |
| Structure : |
|
| Molecular Formula: |
C26H33FN4O3S |
| Molecular Weight: |
500.63 |
| Appearance: |
White to off-white Solid |
| Solubility: |
DMSO |
| Purity: |
>98% |
| Usage: |
LCL161 is an oral small molecule antagonist of Inhibitor of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies.LCL161 is an orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
